Taylor KMHeparin, Protamine and Prostacyclin therapy during cardiopulmonary bypass . In: Taylor KM ed. Cardiopulmonary bypass: principles and management. London: Chapman and Hall, 1986: 277-88.
Marcus AJPlatelet function and its disorders: platelet aggregation. In: Colman RW, Hirsh J, Marder V and Salzman EW eds. Textbook of haemostasis and thrombosis. Philadelphia : Lippincott Co, 1982: Chap. 23.
4.
Gorman RRModulation of human platelet function by prostacyclin and thromboxane A2. Fed Proc1979; 38: 83.
5.
Hosking S., Man W., Taylor KMHistamine release during cardiopulmonary bypass. In: Proc Int Symp Frontiers of HistamineRelease, Paris, 1984.
6.
Salzman EW, Lindon J., Brier D., Merril EWSurface induced platelet adhesion, aggregation and release. Ann NY Acad Sci1977; 283: 114-19.
Baier RD, Dutton RCInitial events and interactions of blood with a foreign surface. J Biomed Mater Res1969; 3: 191-206.
10.
Hennessey VL Jr, Hicks RE, Niewiarowski S., Edmunds LH Jr, Colman RWEffects of surface area and composition on the function of human platelets during extracorporeal circulation. Am J Physiol1977; 232: H622-H628.
11.
Harker LA, Malpass TW, Branson HE, Hessel EA II, Slichter SJMechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction association with selective granule release. Blood1980; 56: 824.
12.
Young JACoagulation abnormalities with cardiopulmonary bypass. In: Utley JR ed. Pathophysiology and techniques of cardiopulmonary bypass. Baltimore: Williams and Wilkins, 1982: 88-105.
13.
Taylor KMBrain damage during open-heart surgery. Thorax1982; 37: 873-76.
14.
Jaffe EA ed. Biology of endothelial cells. Boston: Martinus Nijhoff Publishing, 1984.
15.
Owen WGInteractions of thrombin, antithrombin III and protein C with endothelium . In: Jaffe EA ed. Biology of endothelial cells. Boston: Martinus Nijhoff Publishing, 1984: 259-67.
16.
Huttner I., Gabbiani G.Vascular endothelium. Recent advances in unanswered questions. JLab Invest1982; 47: 409-13.
17.
Davies GC, Sobel M., Salzman EWElevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass. Circulation1980; 61: 808-14.
18.
Needleman P. , Kulkarni PS, Raz A.Coronary tone modulation. Formation and actions of prostaglandins, endoperoxides and thromboxanes. Science1977; 195: 409-12.
19.
Shimamoto T. , Kobaynski M., Takahashi T., Numanu F., Morooka S.Myocardial infarction experimentally induced by thromboxane A2 (Abstr). Circulation1977 ; Suppl3: 123.
20.
Lewy RI, Wiener L., Walinsky P., Lefer AM, Silver MJ, Smith JBThromboxane release during pacing-induced angina pectoris. Possible vasoconstriction influence on the coronary vasculature. Circulation1980; 61: 1165-67.
21.
Junstad M., Wennmalm A.Prostaglandin mediated inhibition of noradrenalin release by different nerve impulse frequencies. Acta Physiol Scan1973 ; 89: 544-49.
22.
Dusting GJ, Moncada S., Mullane KM, Vane VRBiotransformation of arachidonic acid in the circulation of the dog. Br J Pharmacol1978; 63: 359P.
23.
Bunting SR, Gryglewski R., Moncada S., Vane JRArterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins1976; 12: 897-913.
24.
Dusting JD, Moncada S., Vane JRProstaglandins, their intermediates and precursors. Cardiovascular actions and regulatory roles in an abnormal circulatory system. Prog Cardiovasc Dis1979; 21: 405-30.
25.
Moncada S., Higgs EA, Vane JRHuman arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet1977; i: 18-20.
26.
Watkins WD, Peterson MB, Kong DL, et al. Thromboxane and prostacyclin changes during cardiopulmonary bypass with and without pulsatile flow. J Thorac Cardiovasc Surg1982; 84: 250-56.
27.
Ritter JM, Hamilton G., Barrow SE et al. Prostacyclin in the circulation of patients with vascular disorders undergoing surgery. Clin Sci1986; 71: 743-47.
28.
Moncada S., Gryglewski R., Bunting S., Vane JRAn enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature1976; 263: 663-65.
29.
Gryglewski RJ , Bunting S., Moncada S., Flower RJ, Vane JRArterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins1976; 12: 685-708.
30.
Tateson JE, Moncada S., Vane JREffects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets . Prostaglandins1977; 13: 389-97.
31.
Gorman RR, Bunting S.Miller OVModulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins1977; 13: 377-88.
32.
Moncada S., Vane JRDiscovery, biological significance and therapeutic potential of prostacyclin . In: Lewis PJ, O'Grady J eds. Clinical pharmacology of prostacyclin. New York: Raven Press, 1981: 1-8.
33.
Fitzgerald GA, Friedman LA, Miyamori I., O'Grady J., Lewis PJA double-blind placebo controlled crossover study of prostacyclin in man. Life Sciences1979; 25: 665-72.
34.
Szczeklik K., Gryglewski RJActions of prostacyclin in man. In: Vane JR , Bergstrom S eds. Prostacyclin . New York: Raven Press, 1979: 393-405.
35.
Addonizio VP , Fisher CA, Jenkin BK, Strauss JF III, Musial JF, Edmunds LH Jr.Iloprost (ZK 36374), a stable analogue of prostacyclin, preserves platelets during simulated extracorporeal circulation . J Thorac Cardiovasc Surg1985; 89: 926-33.
36.
Schror K., Darius H., Matzky R., Ohlendorf R.The anti-platelet and cardiovascular actions of a new carbacyclin derivative (ZK 36374) equipotent to PGI2 in vitro. Naunyn Schmiedebergs Arch Pharmacol1981; 316: 252-55.
37.
Kawamuna M. , Minamihawa O., Yokochi H., Maki S., Uasua J., Miyuhawaz Y.Hemodynamic effects of prostaglandin E 1 during cardiopulmonary bypass in infants and children. Jpn J Surg1982; 12: 19-25.
38.
Coppe D., Sobel M., Seamans L., Levine F., Salzman E.Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass. J Thorac Cardiovasc. Surg1981; 81: 274-78.
39.
Longmore DBThe value of prostacyclins in cardiopulmonary bypass. In: Longmore DB ed. Towards safer cardiac surgery . Lancaster: MTP, 1981: 355-70.
40.
Longmore DB , Bennett G., Gueirrara D., et al. Prostacyclin. A solution to some problems of extracorporeal circulation. Lancet1979 ; 1: 1002-1005.
DiSesa VJ, Huval W., Lelcuk S. et al. Disadvantages of prostacyclin infusion during cardiopulmonary bypass: a double-blind study of 50 patients having coronary revascularization . Ann Thorac Surg1984; 38: 514-19.
43.
Madhoc R., Taylor K., Brannan J., Bradley H., Forbes CD, Inhibition of platelet aggregation during cardiopulmonary bypass in dogs. In: Hagl S, Klövekorn WP, Mayr N, Sebening F eds. Thirty years of extracorporeal circulation . Munchen: Deutsches Herzzentrum1984: 363-66.
44.
Bennett JG, Longmore DB, O'Grady J.Use of Prostacyclin in cardiopulmonary bypass in man. In: Lewis PJ, O'Grady J eds. Clinical pharmacology of prostacyclin. New York: Raven Press, 1981: 201-201.
45.
Walker ID, Davidson JF, Faichney A., Wheatley DJ, Davidson KGA double-blind study of prostacyclin in cardiopulmonary bypass surgery. Br J Haemat1981; 49: 415-23.
46.
Blauth C., Kohner EM, Arnold J., Taylor KMRetinal micro-embolism during cardiopulmonary bypass demonstrated by fluorescein angiography. Lancet, 1986; ii: 837-39.
47.
Solis RT, Kennedy PS, Beall AC et al. Cardiopulmonary bypass. Microembolization and platelet aggregation . Circulation1975; 52: 103-108.
48.
Hill JD, Aguilar MJ, Baranco A. et al. Neuropathological manifestations of cardiac surgery. Ann Thorac Surg1969; 7: 409-19.
49.
Fessatidis I. , Man WK, Brannan JJ, Taylor KMHaemodynamic and haematological effects of prostacyclin infusion. Presented at: International Congress of Angiology, Athens, Greece: Minerva Medica, June 1985: 519-22.
50.
Radegran K. , Egberg N., Papaconstantinou C.Effects of prostacyclin during cardiopulmonary bypass in man. ScanJ Thorac Surg1981; 15: 263-68.